Ribonucleotide reductase represents a novel therapeutic target in primary effusion lymphoma

Primary effusion lymphoma (PEL) is a highly aggressive B-cell malignancy that is closely associated with one of oncogenic viruses infection, Kaposi's sarcoma-associated herpesvirus (KSHV). PEL prognosis is poor and patients barely survive more than 6 months even following active chemotherapy in...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Lu, Lin, Zhen, Qiao, Jing, Chen, Yihan, Flemington, Erik K., Qin, Zhiqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5578886/
https://www.ncbi.nlm.nih.gov/pubmed/28459467
http://dx.doi.org/10.1038/onc.2017.122

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5578886/
https://www.ncbi.nlm.nih.gov/pubmed/28459467
http://dx.doi.org/10.1038/onc.2017.122

Ejemplares similares